Ann: Mernova Awarded Craft Designation with OCS, page-128

First 128 Last

Share
Profile

Follow
MentalAs

184 Posts.

13

18/05/21

17:14

Post #: 53256209
Share
Originally posted by NashaNasha: ↑

Your fanboys can like all your posts as much as they like these facts stand
last year's loss of $33 million on revenue of less than $3 million
they threw away more weed last year than they sold but never informed shareholders of it
the dozens of prior initiatives that burned tonnes of cash and went nowhere
the fact that the chairman has a vested interest in doing cap raises to directly benefit himself?
the gross profit margin of only 6% last year
Bruce Linton was supposed to light this thing on fire, but so far nothing.
The fact that there are THOUSANDS of cannabis companies around the world all vying for the same markets, nearly all of which are well ahead of CPH.

What have you got to show that this is a winner?

Expand

I'm pretty sure you breached copyright by using FraserJC points, which we have already determined as irrelevant.

check your sources before posting others info.
CPH Price at posting: 17.0¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

MGX

Mount Gibson gets into gold with 'attractive' $50M Central Tanami joint venture

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

IMU

Wednesday's HotCopper trends: Imugene cap raise, Lumos distribution deal | July 16

NOX

Noxopharm gets HERACLES autoimmune trials started with first human doses

LDX

Lumos Diagnostics surges 140% on major US contract deal

First 128 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Ann: Mernova Awarded Craft Designation with OCS, page-128

Top Stories

Mount Gibson gets into gold with 'attractive' $50M Central Tanami joint venture

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Wednesday's HotCopper trends: Imugene cap raise, Lumos distribution deal | July 16

Noxopharm gets HERACLES autoimmune trials started with first human doses

Lumos Diagnostics surges 140% on major US contract deal

Featured News